For research use only. Not for therapeutic Use.
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells[1].
S07-2010 (0-25 μM, 48h) exhibits obvious cytotoxicity on MCF-7/DOX and A549/DDP, with IC50 values of 127.5 and 5.51 μM, respectively[1].
| Catalog Number | I043325 |
| CAS Number | 1223194-71-5 |
| Synonyms | 7-[2-[(6-oxo-4-propyl-1H-pyrimidin-2-yl)sulfanyl]acetyl]-1,3,4,5-tetrahydro-1-benzazepin-2-one |
| Molecular Formula | C19H21N3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H21N3O3S/c1-2-4-14-10-18(25)22-19(20-14)26-11-16(23)13-7-8-15-12(9-13)5-3-6-17(24)21-15/h7-10H,2-6,11H2,1H3,(H,21,24)(H,20,22,25) |
| InChIKey | WVRKQDZPZOUPNW-UHFFFAOYSA-N |
| SMILES | CCCC1=CC(=O)NC(=N1)SCC(=O)C2=CC3=C(C=C2)NC(=O)CCC3 |
| Reference | [1]. Siyu He, et al. Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Med. Chem. Lett. 2022. |
